Long-term cost and utility consequences of short-term clinically important deterioration in patients with chronic obstructive pulmonary disease: results from the TORCH study
Open Access
- 1 May 2019
- journal article
- research article
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 14, 939-951
Abstract
Purpose: Clinically important deterioration (CID) in chronic obstructive pulmonary disease (COPD) is a novel composite endpoint that assesses disease stability. The association between short-term CID and future economic and quality of life (QoL) outcomes has not been previously assessed. This analysis considers 3-year data from the TOwards a Revolution in COPD Health (TORCH) study, to examine this question. Patients and methods: This post hoc analysis of TORCH (NCT00268216) compared costs and utilities at 3 years among patients without CID (CID-) and with CID (CID+) at 24 weeks. A positive CID status was defined as either: a deterioration in forced expiratory volume in 1 second (FEV1) of ≥100 mL from baseline; or a ≥4-unit increase from baseline in St George’s Respiratory Questionnaire (SGRQ) total score; or the incidence of a moderate/severe exacerbation. Patients from all treatment arms were included. Utility change was based on the EQ-5D utility index. Costs were based on healthcare resource utilization from 24 weeks to end of follow-up combined with unit costs for the UK (2016 GBP), and reported as per patient per year (PPPY). Adjusted estimates were generated controlling for baseline characteristics, treatment assignment, and number of CID criteria met. Results: Overall, 3,769 patients completed the study and were included in the analysis (stable CID- patients, n=1,832; unstable CID+ patients, n=1,937). At the end of follow-up, CID- patients had higher mean (95% confidence interval [CI]) utility scores than CID+ patients (0.752 [0.738, 0.765] vs 0.697 [0.685, 0.71]; difference +0.054; PPP=0.003). Conclusion: This study demonstrated that achieving early stability in COPD by preventing short-term CID is associated with better preservation of future QoL alongside reduced healthcare service costs.Keywords
This publication has 28 references indexed in Scilit:
- COPD management costs according to the frequency of COPD exacerbations in UK primary careInternational Journal of Chronic Obstructive Pulmonary Disease, 2014
- The clinical and economic burden of chronic obstructive pulmonary disease in the USAClinicoEconomics and Outcomes Research, 2013
- Multidimensional Analyses of Long-Term Clinical Courses of Asthma and Chronic Obstructive Pulmonary DiseaseAllergology International, 2010
- A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2008
- Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE)European Respiratory Journal, 2008
- Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2007
- Chronic obstructive pulmonary disease: current burden and future projectionsEuropean Respiratory Journal, 2006
- Epidemiology and costs of chronic obstructive pulmonary diseaseEuropean Respiratory Journal, 2006
- The TORCH (TOwards a Revolution in COPD Health) survival study protocol: Fig. 1.—European Respiratory Journal, 2004
- Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paperEuropean Respiratory Journal, 2004